Results of the Pharmaceutical Affairs Subcommittee Regarding the Application of Epogin for Chemotherapy-Induced Anemia
September 30, 2011 (Tokyo) - Chugai Pharmaceutical Co.,
Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama
(hereafter, Chugai)] announced today the result of the review
conducted at the Pharmaceutical Affairs Subcommittee,
Pharmaceutical Affairs and Food Sanitation Council (hereafter,
“the Subcommittee"), convened yesterday to discuss on its
application for the approval of an additional indication, dosage
and administration, and formulation for treatment of
“chemotherapy-induced anemia in solid tumor patients who are
not eligible for curative surgery” for the recombinant human
erythropoietin, "Epogin® Injection" [generic name: epoetin beta (genetic recombination)], which
had been submitted to the Japanese Ministry of Health, Labour and
Welfare in November, 2009. The Subcommittee has concluded that it
is not appropriate to approve Epogin® for this
indication.
Chugai will consider future action regarding this indication for Epogin®.
There shall be no change in the outlook for fiscal year 2011, ending Dec. 31, 2011.
| Name of listed company: |  |
Chugai Pharmaceutical Co., Ltd. |
| Code number: | 4519 (1st Section of Tokyo Stock Exchange) | |
| Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo | |
| President & CEO: | Osamu Nagayama | |
| Inquiries to: | Nobuyuki
Chiba, General Manager, Corporate Communications Dept. |
|
| Tel:+81-(0)3-3273-0881 |
Posted: September 2011
